
First published in the Government *Gazette*, Electronic Edition, on 30 April 2021 at 5 pm.

No. S 284

MISUSE OF DRUGS ACT (CHAPTER 185)

MISUSE OF DRUGS ACT (AMENDMENT OF FIRST AND FIFTH SCHEDULES) ORDER 2021

In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:

Citation and commencement

1. This Order is the Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2021 and comes into operation on 1 May 2021.

Amendment of Part I of First Schedule

2. Part I of the First Schedule to the Misuse of Drugs Act is amended —

(a) by inserting, immediately after the word “Acetylmethadol” in item (2) of paragraph 1, the words “(also known as methadyl acetate)”;

(b) by inserting, immediately after paragraph (g) of item (78) of paragraph 1, the following paragraph:

“(h) 1-Cyclopropionyl-N,N-diethyllysergamide
(also known as 1-Cyclopropionyl-LSD or
1cP-LSD)”;

(c) by deleting items (82) and (140) of paragraph 1;

(d) by inserting, immediately after item (14A) of paragraph 16, the following item:

“(14B) 1-(4-Fluoro-3-methylphenyl)-2-(pyrrolidin-1-yl) pentan-1-one (also known as 4-Fluoro-3-methyl- α -pyrrolidinopentiophenone or 4-Fluoro-3-methyl- α -PVP)”;

(e) by inserting, immediately after item (6E) of paragraph 18, the following items:

“(6F) 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-benzamide (also known as Bromadoline or U-47931E) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring

(6G) 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (also known as N-Methyl U-47931E or N-Methyl Bromadoline) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring”;

(f) by inserting, immediately after item (10) of paragraph 18, the following item:

“(10AAA) 3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]decan-6-yl)benzamide (also known as U-77891) and its dibromo positional isomers in the phenyl ring and their respective azaspiro[4.5]decanyl isomers”;

(g) by inserting, immediately after item (10B) of paragraph 18, the following item:

“(10C) N,N-Diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as Isotonitazene) and its diethylamino structural isomers and their respective isopropoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure”;

(h) by inserting, immediately after item (18) of paragraph 18, the following item:

“(18A) 1-(1,2-Diphenylethyl)piperidine (also known as Diphenidine)”;

(i) by inserting, immediately after item (19) of paragraph 18, the following item:

“(19AA) 2-(Ethylamino)-2-phenyl-cyclohexan-1-one (also known as Deschloro-N-ethyl-ketamine)”;

(j) by inserting, immediately after item (20AB) of paragraph 18, the following item:

“(20B) 2-(3-Fluorophenyl)-3-methylmorpholine (also known as 3-Fluorophenmetrazine or 3F-phenmetrazine) and its fluoro positional isomers in the phenyl ring”;

(k) by inserting, immediately after item (27) of paragraph 18, the following item:

“(27AA) 5-(5-Hydroxypentyl)-2-(2-phenylpropan-2-yl)-pyrido [4,3-b]indol-1-one and its phenylpropyl isomers and their respective hydroxy positional isomers in the pentyl group”;

(l) by inserting, immediately after item (28) of paragraph 18, the following items:

“(28A) 1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine (also known as 2-MeO-Diphenidine or 2-MXP or methoxphenidine) and its methoxy positional isomers in the phenyl ring

(28B) N-Methyl-5-(2-aminopropyl)benzofuran (also known as 5-MAPB) and its 4-yl, 6-yl and 7-yl isomers”;

(m) by inserting, immediately after item (36A) of paragraph 18, the following item:

“(37) 2-Phenyl-2-(methylamino)cyclohexanone (also known as Deschloroketamine)”;

(n) by inserting, immediately after item (38AC) of paragraph 18, the following item:

“(38B) 5-[(2-Phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one-yl]pentanoic acid and its phenylpropyl isomers”;

(o) by inserting, immediately after item (39) of paragraph 18, the following item:

“(40) 2,4,5-Trimethoxy- α -methylphenethylamine (also known as 2,4,5-Trimethoxyamphetamine or TMA-2) and its trimethoxy positional isomers in the phenyl ring”;

(p) by inserting, immediately after item (5) of paragraph 21, the following item:

“(5A) N-(1-Adamantyl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide (also known as 4-Fluoro-ABUTINACA or 4F-ABUTINACA or 4-Fluoro ABINACA)”;

(q) by inserting, immediately after item (7) of paragraph 21, the following item:

“(7A) N-(1-Adamantyl)-4-hydroxybutyl-1H-indazole-3-carboxamide”;

(r) by inserting, immediately after item (15) of paragraph 21, the following item:

“(15A) 4-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) carbamoyl]-1H-indazole-1-yl}butanoic acid”;

(s) by inserting, immediately after item (31) of paragraph 21, the following item:

“(31A) 2-[1-(4-Fluorobutyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid”;

(t) by inserting, immediately after item (36) of paragraph 21, the following items:

“(36A) 2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoic acid

(36B) 1-(5-Hydroxypentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide”;

(u) by inserting, immediately after item (51) of paragraph 21, the following item:

“(51A) Methyl 2-[1-(5-hydroxypentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate”; and

(v) by deleting item (59) of paragraph 21 and substituting the following item:

“(59) 4-{3-[(2-Phenylpropan-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid”.

Amendment of Fifth Schedule

3. Paragraph 1 of the Fifth Schedule to the Misuse of Drugs Act is amended by deleting items (1), (2) and (3).

Made on 27 April 2021.

PANG KIN KEONG
*Permanent Secretary,
Ministry of Home Affairs,
Singapore.*

[MHA 112/2/0049; AG/LEGIS/SL/185/2020/6 Vol. 1]